Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy

Yen Chuan Ou, Jung Ta Chen, Chi Rei Yang, Jiunn Liang Ko, Yih Shou Hsieh, Chinghai Kao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Osteocalcin (OC), a noncollagenous bone matrix protein, is specifically produced by osteoblasts. Previously, we demonstrated that OC immunohistochemical staining was found in primary prostate cancer (PC) and PC metastasis to lymph node and bone. Advanced and metastatic PC is commonly treated by hormonal therapy (H/T). Inevitably, these patients will relapse and develop hormone-refractory (HR) PC. The aim of this study was to realize the OC expression in PC before H/T and after H/T when HRPC developed. Materials and Methods: Twenty patients with PC received H/T and later developed HRPC. The interval of androgen-response was classified by good response (Group A, ≥30 months) and poor response (Group B, <30 months). The mean interval of androgen-response was 48.8 months in Group A (10 patients) and 17.5 months in Group B (10 patients). Formalin-fixed paraffin-embedded PC before H/T and HRPC for each patient were stained for osteocalcin. Results: Osteocalcin immunohistochemical stain was detected in 18 of 20 PC before H/T and 19 of 20 of HRPC. Compared to PC before H/T, the expression of OC in HRPC increased in 5 cases (4 of Group A, 1 of Group B), did not change in 3 (2 of Group A, 1 of Group B) and decreased in 12 (4 of Group A, 8 of Group B). Conclusion: Our data suggest the expression of OC in PC is not correlated to the response of H/T. OC expression was still noted in 95% of HRPC. OC may be a target for treatment of HRPC.

Original languageEnglish
Pages (from-to)3807-3811
Number of pages5
JournalAnticancer Research
Volume23
Issue number5 A
StatePublished - Sep 2003

Fingerprint

Osteocalcin
Prostatic Neoplasms
Therapeutics
Androgens
Bone Matrix
Osteoblasts
Paraffin
Formaldehyde
Coloring Agents
Lymph Nodes
Hormones
Staining and Labeling
Neoplasm Metastasis
Bone and Bones
Recurrence

Keywords

  • Adenocarcinoma
  • Hormone-refractory
  • Osteocalcin
  • Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ou, Y. C., Chen, J. T., Yang, C. R., Ko, J. L., Hsieh, Y. S., & Kao, C. (2003). Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy. Anticancer Research, 23(5 A), 3807-3811.

Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy. / Ou, Yen Chuan; Chen, Jung Ta; Yang, Chi Rei; Ko, Jiunn Liang; Hsieh, Yih Shou; Kao, Chinghai.

In: Anticancer Research, Vol. 23, No. 5 A, 09.2003, p. 3807-3811.

Research output: Contribution to journalArticle

Ou, YC, Chen, JT, Yang, CR, Ko, JL, Hsieh, YS & Kao, C 2003, 'Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy', Anticancer Research, vol. 23, no. 5 A, pp. 3807-3811.
Ou YC, Chen JT, Yang CR, Ko JL, Hsieh YS, Kao C. Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy. Anticancer Research. 2003 Sep;23(5 A):3807-3811.
Ou, Yen Chuan ; Chen, Jung Ta ; Yang, Chi Rei ; Ko, Jiunn Liang ; Hsieh, Yih Shou ; Kao, Chinghai. / Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy. In: Anticancer Research. 2003 ; Vol. 23, No. 5 A. pp. 3807-3811.
@article{8765c01aba314f64b0467ef703faa5ae,
title = "Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy",
abstract = "Background: Osteocalcin (OC), a noncollagenous bone matrix protein, is specifically produced by osteoblasts. Previously, we demonstrated that OC immunohistochemical staining was found in primary prostate cancer (PC) and PC metastasis to lymph node and bone. Advanced and metastatic PC is commonly treated by hormonal therapy (H/T). Inevitably, these patients will relapse and develop hormone-refractory (HR) PC. The aim of this study was to realize the OC expression in PC before H/T and after H/T when HRPC developed. Materials and Methods: Twenty patients with PC received H/T and later developed HRPC. The interval of androgen-response was classified by good response (Group A, ≥30 months) and poor response (Group B, <30 months). The mean interval of androgen-response was 48.8 months in Group A (10 patients) and 17.5 months in Group B (10 patients). Formalin-fixed paraffin-embedded PC before H/T and HRPC for each patient were stained for osteocalcin. Results: Osteocalcin immunohistochemical stain was detected in 18 of 20 PC before H/T and 19 of 20 of HRPC. Compared to PC before H/T, the expression of OC in HRPC increased in 5 cases (4 of Group A, 1 of Group B), did not change in 3 (2 of Group A, 1 of Group B) and decreased in 12 (4 of Group A, 8 of Group B). Conclusion: Our data suggest the expression of OC in PC is not correlated to the response of H/T. OC expression was still noted in 95{\%} of HRPC. OC may be a target for treatment of HRPC.",
keywords = "Adenocarcinoma, Hormone-refractory, Osteocalcin, Prostate",
author = "Ou, {Yen Chuan} and Chen, {Jung Ta} and Yang, {Chi Rei} and Ko, {Jiunn Liang} and Hsieh, {Yih Shou} and Chinghai Kao",
year = "2003",
month = "9",
language = "English",
volume = "23",
pages = "3807--3811",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Expression of Osteocalcin in Prostate Cancer before and after Hormonal Therapy

AU - Ou, Yen Chuan

AU - Chen, Jung Ta

AU - Yang, Chi Rei

AU - Ko, Jiunn Liang

AU - Hsieh, Yih Shou

AU - Kao, Chinghai

PY - 2003/9

Y1 - 2003/9

N2 - Background: Osteocalcin (OC), a noncollagenous bone matrix protein, is specifically produced by osteoblasts. Previously, we demonstrated that OC immunohistochemical staining was found in primary prostate cancer (PC) and PC metastasis to lymph node and bone. Advanced and metastatic PC is commonly treated by hormonal therapy (H/T). Inevitably, these patients will relapse and develop hormone-refractory (HR) PC. The aim of this study was to realize the OC expression in PC before H/T and after H/T when HRPC developed. Materials and Methods: Twenty patients with PC received H/T and later developed HRPC. The interval of androgen-response was classified by good response (Group A, ≥30 months) and poor response (Group B, <30 months). The mean interval of androgen-response was 48.8 months in Group A (10 patients) and 17.5 months in Group B (10 patients). Formalin-fixed paraffin-embedded PC before H/T and HRPC for each patient were stained for osteocalcin. Results: Osteocalcin immunohistochemical stain was detected in 18 of 20 PC before H/T and 19 of 20 of HRPC. Compared to PC before H/T, the expression of OC in HRPC increased in 5 cases (4 of Group A, 1 of Group B), did not change in 3 (2 of Group A, 1 of Group B) and decreased in 12 (4 of Group A, 8 of Group B). Conclusion: Our data suggest the expression of OC in PC is not correlated to the response of H/T. OC expression was still noted in 95% of HRPC. OC may be a target for treatment of HRPC.

AB - Background: Osteocalcin (OC), a noncollagenous bone matrix protein, is specifically produced by osteoblasts. Previously, we demonstrated that OC immunohistochemical staining was found in primary prostate cancer (PC) and PC metastasis to lymph node and bone. Advanced and metastatic PC is commonly treated by hormonal therapy (H/T). Inevitably, these patients will relapse and develop hormone-refractory (HR) PC. The aim of this study was to realize the OC expression in PC before H/T and after H/T when HRPC developed. Materials and Methods: Twenty patients with PC received H/T and later developed HRPC. The interval of androgen-response was classified by good response (Group A, ≥30 months) and poor response (Group B, <30 months). The mean interval of androgen-response was 48.8 months in Group A (10 patients) and 17.5 months in Group B (10 patients). Formalin-fixed paraffin-embedded PC before H/T and HRPC for each patient were stained for osteocalcin. Results: Osteocalcin immunohistochemical stain was detected in 18 of 20 PC before H/T and 19 of 20 of HRPC. Compared to PC before H/T, the expression of OC in HRPC increased in 5 cases (4 of Group A, 1 of Group B), did not change in 3 (2 of Group A, 1 of Group B) and decreased in 12 (4 of Group A, 8 of Group B). Conclusion: Our data suggest the expression of OC in PC is not correlated to the response of H/T. OC expression was still noted in 95% of HRPC. OC may be a target for treatment of HRPC.

KW - Adenocarcinoma

KW - Hormone-refractory

KW - Osteocalcin

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0344874111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344874111&partnerID=8YFLogxK

M3 - Article

C2 - 14666681

AN - SCOPUS:0344874111

VL - 23

SP - 3807

EP - 3811

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -